Executive Q&A With SGS' Hudson, NH Bioanalytical Services Facility

By Sujata (Suzzy) Bhavekar, M.S, CSM, Study Director, Bioanalytical, SGS North America

SGS has strategically expanded its global bioanalytical testing capabilities with the establishment of a specialized facility in Hudson, New Hampshire. This lab enhances SGS's North American presence while integrating seamlessly with its bioanalytical facilities in Europe and Asia. Located near Boston's biotech hub, the Hudson facility offers an array of services, including pharmacokinetics (PK), biomarker analysis, clinical and post-marketing studies, and analytical method development. Advanced technologies, such as LC-MS/MS and hybrid LBA-LC-MS/MS approaches, enable the analysis of a wide range of compounds, from small molecules to complex biologics.

By operating under SGS's unified quality standards and regulatory frameworks, the lab ensures compliance and consistency across the global network. SGS’s one-stop model streamlines the drug development process, offering cost-effective, efficient, and high-quality solutions to pharmaceutical and biopharmaceutical companies. With ongoing investments in innovative technologies and expanded capabilities, the Hudson facility positions SGS at the forefront of bioanalytical testing innovation.